Saiag, P <br/><br/>
Prospective assessment of a gene signature potentially predictive of clinical benefit in metastatic melanoma patients following MAGE-A3 immunotherapeutic (PREDICT).  [electronic resource] 

 -  Annals of oncology : official journal of the European Society for Medical Oncology  10 2016 
 - 1947-53 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1569-8041 
<br/><br/><label>Standard No.: </label>10.1093/annonc/mdw291  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antigens, Neoplasm--genetics<br/>Disease-Free Survival<br/>Female<br/>Gene Expression Regulation, Neoplastic<br/>Genomics<br/>Humans<br/>Immunotherapy--adverse effects<br/>Male<br/>Melanoma--genetics<br/>Middle Aged<br/>Neoplasm Proteins--genetics<br/>Neoplasm Staging<br/>Transcriptome--genetics